Celsion (CLSN) Issues Positive Update on Phase 2 DIGNITY in Breast Cancer
Tweet Send to a Friend
Celsion (NASDAQ: CLSN) announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
